Présentation de l'entreprise
Emergent BioSolutions Inc. operates as a life sciences company dedicated to providing comprehensive preparedness and response solutions designed to address accidental, deliberate, and naturally occurring public health threats across the United States, Canada, and international markets. The organization functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized pharmaceutical products and generic manufacturing rather than broad consumer staples. The company demonstrates a specific operational scale with a market capitalization of $434.36M, an annual revenue of $742.90M, and an workforce of 900 employees. These valuation and revenue figures indicate that Emergent BioSolutions holds a significant but not dominant position within its niche, suggesting a mid-sized enterprise with substantial revenue generation capabilities relative to its market cap, which often points to a company with strong cash flow generation but potentially lower market sentiment or recent earnings compression.
Santé financière
The financial performance metrics reveal a complex cost structure where the company generated $742.90M in revenue and $52.60M in net income over the trailing twelve months, resulting in an EBITDA of $208.90M. The substantial gap between the $742.90M revenue and the $52.60M net income highlights a significant cost of goods sold and operational expenses, although the high EBITDA suggests robust earnings before interest, taxes, depreciation, and amortization. The company reported a free cash flow of $205.39M, which indicates strong financial flexibility and the ability to fund operations, repay debt, or invest in research without relying heavily on external financing. Margin analysis shows a gross margin of 49.4%, reflecting efficient production costs, while the operating margin stands at -15.2%, indicating that operational expenses have temporarily outweighed gross profits, yet the profit margin remains positive at 7.1%. On the balance sheet, the company holds $205.40M in cash against $583.70M in total debt, resulting in a debt-to-equity ratio of 111.69%, which characterizes a leveraged financial position rather than a conservative one. Despite the high leverage, the current ratio of 5.01 suggests excellent short-term liquidity, as the company possesses more than five times the liquid assets required to cover its current liabilities. Furthermore, the return on equity of 10.5% and return on assets of 5.3% demonstrate that management is generating returns that exceed the cost of capital, even within a highly leveraged structure.
Évaluation de la valorisation
Valuation multiples for Emergent BioSolutions Inc. show a trailing P/E ratio of 9.02 and a forward P/E of 2.81, a stark difference that implies the market expects a significant expansion in earnings or a substantial correction in valuation multiple as anticipated future earnings are priced at a much lower multiple than historical performance. The price-to-book ratio of 0.84 indicates that the stock is trading below its book value, suggesting the market assigns a discount to the company's tangible assets or anticipates future challenges that prevent full realization of that book value. Alternative valuation metrics, including a price-to-sales ratio of 0.58 and an EV/EBITDA of 3.89, suggest the stock is priced at a deep discount relative to its sales and earnings power, often seen in cyclical or turnaround situations. The stock's trading range over the past year spans from a 52-week low of $4.02 to a 52-week high of $14.06, providing a wide band of volatility within which the current price fluctuates. The company exhibits a beta of 2.36, which signifies that its price volatility is more than twice that of the broader market, indicating high sensitivity to systemic market movements and sector-specific shocks.
Growth & Income
The growth profile for the trailing twelve months shows a revenue growth rate of -23.6%, while earnings growth is listed as N/A due to the specific reporting context of the data provided. The negative revenue growth indicates a contraction in sales volume or pricing pressure, whereas the absence of a reported earnings growth figure alongside the positive net income suggests a decoupling of top-line performance from bottom-line profitability in the current period. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the organization reinvests all available earnings back into the business rather than distributing them to shareholders. This strategy aligns with a growth-oriented or capital-recycling model where cash reserves are prioritized for operational needs and debt management over shareholder payouts. The overall growth and income profile presents a scenario of a profitable but contracting revenue business that maintains strong cash generation and returns on capital without relying on dividend income for investors.